收藏切换
Cost-utility analysis of pioglitazone-metformin in the treatment of Chinese type 2 diabetes mellitus patients
收藏切换
Zixuan HE1, Wei LI1, He ZHU1, Sheng HAN1, 2, *
World Clinical Drug | 2022, 43(3) : 300 - 308
Less
收藏切换
World Clinical Drug | 2022, 43(3): 300-308
• Article •
Cost-utility analysis of pioglitazone-metformin in the treatment of Chinese type 2 diabetes mellitus patients
Full
Zixuan HE1, Wei LI1, He ZHU1, Sheng HAN1, 2, *
Affiliations
  • 1.International Research Center for Pharmaceutical Administration, Peking University, Beijing 100191, China
  • 2.School of Pharmacy, Peking University, Beijing 100191, China
Published: 2022-03-10 doi: 10.13683/j.wph.2022.03.016
Outline
收藏切换
Objective

To evaluate the long-term cost-effectiveness of pioglitazone-metformin versus sitagliptin-metformin in treating Chinese type 2 diabetes mellitus (T2DM) patients, in order to provide reference for rational drug use in clinic.

Methods

From the health system perspective, we simulated the quality-adjusted life years (QALYs) of patients over 30 years using the validated CORE diabetes model. Inputs of baseline risk factors were extracted from Chinese epidemiological studies, clinical efficacy and medication cost data were obtained from relevant published resources in China, utility data are model default values. Both outcomes and costs were discounted at 5% annually. In this paper, one-way sensitivity analyses were conducted for discount rates and study durations. Monte Carlo simulation was used for probability sensitivity analysis, and scenario analysis was done for a treatment algorithm without second-line therapy.

Results

Basic case analysis indicated that, compared with the sitagliptin-metformin regimen, pioglitazone-metformin regimen lowered the incidence of complication, increased cumulative QALYs by 0.02 (9.49 QALYs vs 9.47 QALYs), and reduced total cost by 7 804 yuan (298 214 yuan vs 306 018 yuan). It was an absolute economic advantage scheme and robust sensitivity analysis results.

Conclusion

In the long-term health economic context, compared with sitagliptin-metformin, pioglitazone- metformin is a more economical treatment option with improved QALYs and reduced direct medical costs among Chinese T2DM patients.

pioglitazone-metformin  /  sitagliptin-metformin  /  type 2 diabetes mellitus  /  cost-effectiveness analysis  /  pharmacoeconomic evaluation
贺子璇, 李薇, 朱贺, 韩晟. 吡格列酮二甲双胍治疗中国2型糖尿病的成本-效用分析. 世界临床药物, 2022 , 43 (3) : 300 -308 . DOI: 10.13683/j.wph.2022.03.016
Zixuan HE, Wei LI, He ZHU, Sheng HAN. Cost-utility analysis of pioglitazone-metformin in the treatment of Chinese type 2 diabetes mellitus patients[J]. World Clinical Drug, 2022 , 43 (3) : 300 -308 . DOI: 10.13683/j.wph.2022.03.016
Year 2022 volume 43 Issue 3
10
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.03.016
  • Receive Date:2021-11-03
  • Online Date:2026-11-19
  • Published:2022-03-10
Article Data
Affiliations
History
  • Received:2021-11-03
Affiliations
    1.International Research Center for Pharmaceutical Administration, Peking University, Beijing 100191, China
    2.School of Pharmacy, Peking University, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.03.016
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT